Now look at what my Google search on “Brainchip Akida” dug up from the depths of the internet:
The link looked pretty dodgy to me, so I didn’t click on it. Instead, I did another Google search, this time on “C-Leg 4, Kenovo, Genium and Genium X3”, and it turns out they are all microprocessor-controlled knee prostheses by German orthopaedic technology company Ottobock, which according to Wikipedia (
https://en.m.wikipedia.org/wiki/Ottobock) is considered “the world market leader in the field of prosthetics and one of the leading suppliers in orthotics, wheelchairs and exoskeletons.”
www.ottobock.com
These microprocessor-controlled prosthetic knee joints have been on the market for many years now (the C-Leg was the world’s first in 1997, followed by the first generations of Genium (2011) Genium X3 (2013) and Kenovo (2015), with model updates since), but maybe Ottobock figured it was time for an ultra-low power upgrade?!
A quick search did not yield any (other) connections between Ottobock and Brainchip, so I am not sure whether this is a valid dot join or possibly some GenAI’s hallucination
(would anyone like to volunteer to click on that link?!).
Employing neuromorphic technology as a means of restoring tactile sensation is definitely something the bionic limbs industry is extremely interested in (not to mention the affected patients!), and of course research of that kind is already being conducted at universities (see the paper below, which
@Sirod69 shared with us two months ago), so chances are, the world market leader in prosthetics will have already checked out the available providers of this promising tech and possibly play around with less complicated use cases first.
A world leader in innovation and technology, Ottobock is growing around the globe. Find out more about our products, services and company, Ottobock SE & Co KGaA.
corporate.ottobock.com
Progress with tradition
Ottobock sets standards
For more than 100 years, Ottobock develops innovative products. Meanwhile, the med-tech company also takes care of the full treatment cycle all over the globe. These services are provided under the Ottobock SE & Co. KGaA name, which began in 2018 to channel the company’s med-tech expertise also into sustainably healthy workplaces.
We continually develop our company and perfect our technology to improve the lives of our users. In 2022, we invested 7% of our turnover in research and development.
Since 1919 products and technologies from Ottobock have been helping people gain new freedom of movement and avoid potential complications. Initially, the company revolutionised the market – above all treatment for patients – thanks to the series production of prosthetic components. Since then, the focus has turned to microprocessor-controlled knee joints such as the C-Leg (which can be controlled via an app), the computer-controlled C-Brace leg orthosis, the multi-articulating bebionic hand, Juvo power wheelchairs and the Paexo exoskeleton range for ergonomic workplaces.
Our single-minded determination to improve quality of life has made us a global leader in technology for wearable human bionics, which enhance or replace parts of the human body.
In numbers
Ottobock SE & Co. KGaA
Turnover in 2022
EUR 1.3 billion
Employees
Over 9,000 in almost 60 countries across the world
patient care centres
more than 400
Global market leader
in prosthetics
?! 
